Predictors of survival after resection of primary sarcomas of the chest wallA large, single-institution series

被引:19
|
作者
Shewale, Jitesh B. [1 ,2 ]
Mitchell, Kyle G. [1 ]
Nelson, David B. [1 ]
Conley, Anthony P. [3 ]
Rice, David C. [1 ]
Antonoff, Mara B. [1 ]
Hofstetter, Wayne L. [1 ]
Walsh, Garrett L. [1 ]
Swisher, Stephen G. [1 ]
Roth, Jack A. [1 ]
Mehran, Reza J. [1 ]
Vaporciyan, Ara A. [1 ]
Weissferdt, Annikka [4 ]
Sepesi, Boris [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77005 USA
[2] Univ Texas Hlth Sci Ctr UTHlth, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
chest wall sarcoma; surgical resection; multimodality therapy; SOFT-TISSUE SARCOMAS; SURGICAL-TREATMENT; TUMORS; MANAGEMENT;
D O I
10.1002/jso.25162
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivesChest wall sarcomas are rare and may demonstrate heterogeneous features. Surgery remains the mainstay of treatment with chemotherapy and radiotherapy used as adjuncts. Herein, we report outcomes of a large cohort of patients with primary chest wall sarcoma who underwent resection. MethodsRecords of 121 patients who underwent resection forprimary chest wall sarcoma between 1998 and 2013 were reviewed. A thoracic pathologist reexamined all tumors and categorized them according to grade. Univariable and multivariable Cox analyses were conducted to identify predictors of overall survival (OS). ResultsThe median age was 45.0 (range, 11-81) years, and most tumors (63.6%, 77) were high grade. The median tumor size was 7cm (range, 1-21cm). Fifty-nine (48.8%) patients received neoadjuvant chemotherapy and 12 (9.9%) received neoadjuvant radiotherapy. A complete resection was achieved in 103 (85.1%) patients. Neoadjuvant chemotherapy (P=0.532) and radiation (P=1.000) were not associated with a complete resection. Five-year OS among patients undergoing R0 and R1 resections was 61.9% and 27.8%, respectively. Multivariable analysis identified high grade (HR, 15.21; CI, 3.57-64.87; P<0.001), R1 (HR, 3.10; CI, 1.40-6.86; P=0.005), R2 resection (HR, 5.18; CI, 1.91-14.01; P=0.001), and age (HR, 1.02; CI, 1.01-1.03; P=0.002) as predictors of OS. ConclusionsIn this series of resected chest wall sarcomas, complete resection and tumor grade remain the most important survival predictors. Individual decisions are required for the utilization of neoadjuvant therapy.
引用
收藏
页码:518 / 524
页数:7
相关论文
共 50 条
  • [31] Outcomes of Single-Institution Retrospective Case Series on Observation Alone Following Atypical Meningioma Resection
    Stone, Lauren
    Moulding, Hugh D.
    Deb, Nimisha
    Lee, Charles T.
    NEUROSURGERY, 2019, 66 : 139 - 140
  • [32] Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases
    Wright, JA
    Bradfield, SM
    Park, JR
    Hawkins, DS
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (04) : 286 - 291
  • [33] A COMPARISON OF SURVIVAL OUTCOMES AFTER BIOPSY VERSUS RESECTION IN PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
    Hong, Christopher
    Barbiero, Frank
    Chiang, Veronica
    Moliterno, Jennifer
    Piepmeier, Joseph
    Corbin, Zachary
    Baehring, Joachim
    NEURO-ONCOLOGY, 2018, 20 : 250 - 250
  • [34] Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis
    Ishikawa, Eiichi
    Sugii, Narushi
    Matsuda, Masahide
    Kohzuki, Hidehiro
    Tsurubuchi, Takao
    Akutsu, Hiroyoshi
    Takano, Shingo
    Mizumoto, Masashi
    Sakurai, Hideyuki
    Matsumura, Akira
    BMC NEUROLOGY, 2021, 21 (01)
  • [35] Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis
    Eiichi Ishikawa
    Narushi Sugii
    Masahide Matsuda
    Hidehiro Kohzuki
    Takao Tsurubuchi
    Hiroyoshi Akutsu
    Shingo Takano
    Masashi Mizumoto
    Hideyuki Sakurai
    Akira Matsumura
    BMC Neurology, 21
  • [36] Atypical Fibroxanthoma (AFX): Clinicopathologic Characteristics and Natural History in a Large Single-Institution Series
    McCardle, T. W.
    Zager, J. S.
    Bui, M.
    Shah, S.
    Patel, A.
    Sondak, V. K.
    Messina, J. L.
    Lee, H.
    LABORATORY INVESTIGATION, 2009, 89 : 107A - 107A
  • [37] Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: A retrospective, single-institution experience
    Takai, S
    Satoi, S
    Toyokawa, H
    Yanagimoto, H
    Sugimoto, N
    Tsuji, K
    Araki, H
    Matsui, Y
    Imamura, A
    Kwon, AH
    Kamiyama, Y
    PANCREAS, 2003, 26 (03) : 243 - 249
  • [38] Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution
    Perhavec, Andraz
    Provenzano, Salvatore
    Baia, Marco
    Sangalli, Claudia
    Morosi, Carlo
    Barisella, Marta
    Colombo, Chiara
    Radaelli, Stefano
    Pasquali, Sandro
    Callegaro, Dario
    Gronchi, Alessandro
    Fiore, Marco
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (02) : 1151 - 1157
  • [39] Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution
    Andraz Perhavec
    Salvatore Provenzano
    Marco Baia
    Claudia Sangalli
    Carlo Morosi
    Marta Barisella
    Chiara Colombo
    Stefano Radaelli
    Sandro Pasquali
    Dario Callegaro
    Alessandro Gronchi
    Marco Fiore
    Annals of Surgical Oncology, 2021, 28 : 1151 - 1157
  • [40] Atypical Fibroxanthoma(AFX):Clinicopathologic Characteristics and Natural History in a Large Single-Institution Series
    McCardle, T. W.
    Zager, J. S.
    Bui, M.
    Shah, S.
    Patel, A.
    Sondak, V. K.
    Messina, J. L.
    Lee, H.
    MODERN PATHOLOGY, 2009, 22 : 107A - 107A